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Introduction
MS samples were utilised from the Perth Demyelinating Disease Database 
(PDDD) (Western Australia). DNA was isolated from buffy coats and 
the C-terminal end of the EBNA-1 gene was amplified using a novel 
semi-nested PCR approach with a fully automated setup utilising 
Biomek FX robots. First round PCR was performed using Roche High 
Fidelity Taq in a 25µl reaction with primers EBV109111F-EBV109951R, 
resulting in a 840bp fragment. A semi-nested PCR was followed using 
the primer combination EBV109111F-EBV109869R resulting in a final 
749 base pair product (Fig.1). Successful PCR samples were purified 
using AMPure and Sanger sequenced on an automated 96 capillary 
ABI 373 DNA sequencer, followed by analysis using the ASSIGN 
V4.0.1.36 software (Conexio Genomics) (Fig.2). Threshold for mixture 
detection in sanger sequencing has been established to be ~20%. 
To study sequence minorities in quasispecies present at >=1%, ultra-deep
sequencing was performed using the FLX-454 Roche technology for a
subset of 23 MS patients and a B95-8 control. The same first round
PCR products obtained were used for high throughput sequencing and
Sanger sequencing approaches. For the second round semi-nested
PCR, primers were 5′ end tagged with 10 nucleotides of unique
sequence (one each primer pair and sample) to enable pooling of
samples in one library. Samples were purified using AMPure and
concentrations measured with Nanodrop. Copy number per sample
was calculated and 1x1011 copies per sample were pooled. After
equimolar pooling, the combined samples were purified with
minielute spin column (Qiagen). Final concentration for the pooled
fragments was 150.4 ng/ul. One library of all pooled samples was
prepared and 454 sequenced (Fig.2).
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Both genetic and environmental factors contribute to Multiple Sclerosis (MS)
risk. Susceptibility to MS is conferred by immune system associated genes, with
human leukocyte antigen (HLA) DRB1*1501 identified as a major MS risk allele.
Infection with Epstein-Barr Virus (EBV) has also been shown to increase MS risk,
and in particular anti-EBV nuclear antigen-1 (EBNA-1) antibodies are strongly
associated with the disease. Additionally, it has been shown that EBNA1-specific
CD4+ T-cells can cross-recognize MS-associated myelin antigens, and are
selectively expanded in MS patients.
We therefore sought to assess MS patient-specific EBNA-1 sequence variation,
including the potential influence of minority sequence variants, in shaping
immune responses to known and predicted HLA-DRB1*1501-restricted
epitopes.
Epitope coding sequence variability was directly compared using 14 samples
sequenced with Sanger sequencing and 454 FLX technology for three
previously described epitopes: a putative B cell epitope GRRPFFHPVGE
(aa 401-411), and two HLA-DRB1*1501 epitopes (AEGLRALLARSHVER
(aa 482-496), MVFLQTHIFAEVLKD (aa 563-477).
As shown in Figure 5, both methods were concordant in detecting sequence
variation potentially relevant to epitope recognition and presentation,
with only a minority of sequences sharing identity with the B95-8
reference strain. 454 FLX technology identified mixtures of >1%,
although generally at a low percentage with no mixtures > 10% within
the epitopes.
Discussion
This study confirms the feasibility of direct amplification and sequencing of
EBNA-1 from patient samples in identifying patient-specific sequence
variation, with evidence of high level of concordance between sanger
and FLX 454 sequencing techniques.
The frequent detection of sequences that are divergent from B95-8 reference
strain suggests that studies investigating epitope-specific immune
responses can be usefully guided by autologous patient sequence
information.
Low-level sequence variation was identified by sensitive FLX technology but was
generally rare. It remains to be determined if these minority species
affect EBV-specific immune responses or disease outcomes.
Amino acid variability was low and Sanger sequencing results revealed no mixed
positions. Utilizing 454 FLX deep sequencing, minor species could be
detected at >10% frequency in 2.9% (21 positions of all 714 positions
investigated), increasing to 25.5% of all positions investigated with
minor species detected at >=1% (Table 2).
At a 1% cut off, 105 positions contained mixed amino acids for one sample only
whereas in 30 different positions there were at least 2 samples with
an amino acid mixture in the same position (Table 2).
14 samples tested on FLX had high coverage with average reads between 80-
1632 for the C-terminal EBNA-1 fragment. 10 samples had low amount
of coverage and or reads (average reads <15). Four of these samples
(38585, 38695, 38939, 38593) were successful for PCR amplification
but could not be sequenced with conventional Sanger sequencing
technology. Unmatched contigs were blasted and were found to
represent chromosomal DNA.
In this study, both sanger and 454 FLX approaches were utilised to identify
EBNA-1 sequence variation potentially relevant to immune response
in MS patients.
Sanger sequencing revealed no mixed positions but identified different viral
clusters mainly divergent from the reference strain B95-8.
Using the sensitive 454 FLX technology, several minority species could be
detected. Additionally, four samples could be sequenced using 454
FLX that could not be sequenced with sanger sequencing technology.
However, these samples preferentially amplified chromosomal DNA
with low EBV reads, suggesting low EBV viral load in these samples.
Most quasispecies were present at less than 1%, consistent with known limited
dsDNA viral sequence variation.
Analysing sequence variation in previously described EBNA-1 epitopes
demonstrated concordant results using these two methods, with
limited evidence of viral quasispecies.
Conclusions
Fig.1: Semi-nested, C-terminal EBNA-1 PCR. Numbers reflect the position of the primers in B95-8.
Fig. 5: Comparison of HLA-DRB1*1501 class-II epitope variation between Sanger and 454 FLX sequencing
(epitope position in EBNA-1: 482-496) for 14 samples.
Blue boxes = mixtures in 454 FLX sequencing. Grey boxes = variation to reference sequence B95-8.
n = number of samples with this epitope.
Table 2: Mixed amino acid positions for 14 samples with high coverage tested on 454 FLX.
Minorities at 1%, 2%, 5% and 10% cut off. Percentage of mixed positions was calculated in
relation to the 714 investigated nucleotides of EBNA-1.
Results
EBV could successfully be amplified in 72 samples without previous culture to
enrich for EBV episomes. EBV Sanger sequences clustered in four main
groups. Interestingly, most of the samples did not cluster with the EBV
reference strain B59-8 (Fig.3). Genotyping of position 487 of EBNA-1
identified the strain 487-threonine (n=52) and 487-alanine (n=14) as
most prevalent, with alanine also present in the B95-8 reference strain
(Table 1).
Fig. 2: workflow sanger and 454 FLX sequencing
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Fig. 4: Maximum and average reads for 24 MS samples tested on 454 FLX.
samples with mutation in the same position
1 2 3 4 5 6 7 8 9 10 11 12 13 14 mixed positions % mixed positions
1% positions with mutation 105 30 15 11 6 4 0 2 1 4 0 3 1 0 182 25.5%
2% positions with mutation 35 17 3 3 4 2 0 1 1 0 2 1 0 0 69 9.7%
5% positions with mutation 21 7 0 1 1 1 1 0 0 0 0 0 0 0 32 4.5%
10% positions with mutation 19 1 1 0 0 0 0 0 0 0 0 0 0 0 21 2.9%
For FLX data analysis all homopolymers not present in the consensus 
sequence have been excluded. Minorities present at < 1% were not 
taken into consideration and insertion deletions were also excluded.
Fig. 3: Phylogenetic tree of C-terminal EBNA-1 MS 
sequences. Circled is the EBV reference strain B95-8
Table 1: Genotyping position 487 of
the EBNA-1 gene in 72 samples.
